ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI
Invited conference paper presented and published in conference proceedings

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Background
NSCLC patients (Pts) harboring EGFR mutation invariably develop resistance to EGFR TKI at a median time of 9-13 months. Prior studies have showed that local ablative therapy (LAT) upon oligoprogression (OP) can extend the duration of TKI therapy effectively. We postulate that residual positron emission tomography (PET) avid lesions after initial treatment of EGFR TKI may harbor resistant clones and preemptive LAT may improve progression free survival (PFS).

Method
This single-arm phase II study aims to determine the efficacy of preemptive LAT to residual metabolic active oligo-metastases after initial TKI. Pts with stage IIIB/ IV EGFR M+ NSCLC who possessed oligoresidual (OR) disease (≤ 4 PET-avid lesions with SUV ≥2.5) after a 3-mth TKI therapy were enrolled. Those with initial PR underwent screening PET-CT. PET avid ORs would be treated by LAT, either by stereotactic ablative radiotherapy (SABR) or surgery per clinicians’ discretion. TKI was continued after LAT until it was considered ineffective. PET-CT was done on the 3rd and 12th month post-LAT (or at progression), apart from regular imaging. Further LAT was allowed if OP was detected. Primary endpoint was PFS rate at 1 year from enrollment. Overall survival (OS), treatment safety and comparison with screen failure cohorts were secondary endpoints.

4c3880bb027f159e801041b1021e88e8 Result
18 Pts were enrolled from 2014-17. Recruitment was stopped before the planned number (n = 34) due to slow accrual. Two were not analyzed due to consent withdrawal and significant protocol violation. Median follow up was 28.7 mth. Among the 16 analyzed Pts, the 1 year PFS rate (i.e. 15 mth post TKI) was 62.5%. OS data was not yet mature. All LAT were done by SABR, and none experienced ≥grade 3 SABR related toxicities. Compared with screen failure cohort (n = 43, metabolic CR or PR with residual disease not fulfilling LAT criteria), the 1 year and 2 year PFS favored treatment arm, though statistically not significant (62.5% vs 47.1%, 30.0% vs 7.9%; p = 0.15).

Conclusion
The 1-yr PFS rate is encouraging. A trend of improved long term PFS is noted in Pts receiving preemptive LAT to residual PET-avid OM after initial TKI compared with Pts without LAT. Further studies are warranted.

Clinical Trial information: NCT01941654
著者Oscar S.H. Chan, Kwok Chi Lam, Jacky Yu Chung Li, Frankie Choi, Catherine Wong, Amy Chang, Frankie Mo, Ki Wang, Rebecca Yeung, Tony S. Mok
會議名稱WCLC 2018, 19th World Conference on Lung Cancer
會議開始日23.09.2018
會議完結日26.09.2018
會議地點Toronto
會議國家/地區加拿大
會議論文集題名Journal of Thoracic Oncology
系列標題Oral Abstract Session
叢書冊次Abst: OA07.02
出版年份2018
月份10
卷號13
期次Suppl 10
出版社Elsevier
頁次S336 - S336
國際標準期刊號1556-0864
電子國際標準期刊號1556-1380
語言英式英語
關鍵詞EGFR TKI

上次更新時間 2020-04-07 於 00:41